Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMDNASDAQ:HURANASDAQ:PHATNASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$11.64+0.4%$12.52$3.61▼$17.43$788.12M1.581.34 million shs1.08 million shsHURATuHURA Biosciences$2.47-5.4%$3.10$1.80▼$7.93$108.33M0.17264,632 shs603,783 shsPHATPhathom Pharmaceuticals$8.77-1.6%$6.25$2.21▼$19.71$622.74M0.451.54 million shs499,121 shsTSHATaysha Gene Therapies$2.40-1.2%$2.50$1.05▼$3.31$525.92M0.972.92 million shs726,725 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix0.00%-6.88%-5.98%+98.63%+181.84%HURATuHURA Biosciences0.00%+11.26%-12.41%-26.92%+246,999,900.00%PHATPhathom Pharmaceuticals0.00%-10.01%+86.49%+79.61%-14.49%TSHATaysha Gene Therapies0.00%+0.84%-13.98%+96.72%+11.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRMDCorMedix2.5934 of 5 stars4.41.00.00.02.50.00.6HURATuHURA Biosciences1.2971 of 5 stars3.70.00.00.01.00.00.0PHATPhathom Pharmaceuticals3.5962 of 5 stars4.51.00.00.01.15.00.6TSHATaysha Gene Therapies3.3912 of 5 stars4.51.00.00.03.03.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.88Moderate Buy$17.1447.28% UpsideHURATuHURA Biosciences 3.40Buy$12.67412.82% UpsidePHATPhathom Pharmaceuticals 3.00Buy$17.5099.66% UpsideTSHATaysha Gene Therapies 3.00Buy$8.20241.67% UpsideCurrent Analyst Ratings BreakdownLatest HURA, CRMD, PHAT, and TSHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/30/2025CRMDCorMedixD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/30/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold6/30/2025CRMDCorMedixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.006/24/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.006/23/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.006/23/2025HURATuHURA BiosciencesBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/20/2025CRMDCorMedixRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$13.00 ➝ $17.006/10/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/9/2025PHATPhathom PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $17.006/9/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$43.47M18.16N/AN/A$1.40 per share8.31HURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/APHATPhathom Pharmaceuticals$55.25M11.07N/AN/A($3.71) per share-2.36TSHATaysha Gene Therapies$8.33M61.85N/AN/A$0.35 per share6.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$17.93M$0.2252.9112.38N/A20.81%22.57%17.02%8/13/2025 (Estimated)HURATuHURA Biosciences-$21.68MN/A0.00∞N/AN/A291.69%122.09%N/APHATPhathom Pharmaceuticals-$334.33M-$5.24N/AN/AN/A-422.42%N/A-90.11%8/6/2025 (Estimated)TSHATaysha Gene Therapies-$89.30M-$0.34N/AN/AN/A-1,201.08%-104.93%-50.09%8/11/2025 (Estimated)Latest HURA, CRMD, PHAT, and TSHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HURATuHURA Biosciences-$0.13-$0.15-$0.02-$0.15N/AN/A5/15/2025Q1 2025TSHATaysha Gene Therapies-$0.08-$0.08N/A-$0.08$1.48 million$2.30 million5/6/2025Q1 2025CRMDCorMedix$0.25$0.30+$0.05$0.30$38.90 million$39.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A4.213.99HURATuHURA BiosciencesN/A3.003.00PHATPhathom PharmaceuticalsN/A3.583.54TSHATaysha Gene Therapies0.775.355.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%HURATuHURA Biosciences0.62%PHATPhathom Pharmaceuticals99.01%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix5.30%HURATuHURA Biosciences0.20%PHATPhathom Pharmaceuticals23.00%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3067.82 million64.23 millionOptionableHURATuHURA BiosciencesN/A43.68 million43.59 millionN/APHATPhathom Pharmaceuticals11069.81 million53.76 millionOptionableTSHATaysha Gene Therapies180214.66 million206.55 millionOptionableHURA, CRMD, PHAT, and TSHA HeadlinesRecent News About These CompaniesTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 3 at 1:05 PM | globenewswire.comBeyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies StockJuly 1, 2025 | benzinga.comTaysha Gene Therapies (NASDAQ:TSHA) Earns "Buy" Rating from Needham & Company LLCJuly 1, 2025 | marketbeat.comCantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical DataJune 29, 2025 | insidermonkey.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 4.3% - Here's What HappenedJune 26, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's WhyJune 20, 2025 | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from BrokeragesJune 19, 2025 | marketbeat.comEquities Analysts Offer Predictions for TSHA FY2025 EarningsJune 16, 2025 | marketbeat.comMillennium Management LLC Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)June 12, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Trading Up 10.5% - Time to Buy?June 11, 2025 | marketbeat.comCantor Fitzgerald Estimates TSHA FY2026 EarningsJune 11, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.9% - What's Next?June 10, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)June 10, 2025 | marketbeat.comTaysha Gene Therapies Grants Stock Options to New Employees Under Inducement PlanJune 8, 2025 | nasdaq.comWellington Management Group LLP Purchases 122,402 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)June 7, 2025 | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comSquarepoint Ops LLC Has $366,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)June 6, 2025 | marketbeat.comTaysha Gene Therapies Releases TSHA-102 Clinical Program UpdatesJune 4, 2025 | insidermonkey.comRetail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial DataJune 4, 2025 | msn.comPaul B. Manning Buys 750,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) StockJune 4, 2025 | insidertrades.comTaysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific MeetingJune 3, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHURA, CRMD, PHAT, and TSHA Company DescriptionsCorMedix NASDAQ:CRMD$11.64 +0.05 (+0.43%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$11.62 -0.02 (-0.13%) As of 07/3/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.TuHURA Biosciences NASDAQ:HURA$2.47 -0.14 (-5.36%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$2.49 +0.02 (+0.81%) As of 07/3/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Phathom Pharmaceuticals NASDAQ:PHAT$8.76 -0.15 (-1.63%) Closing price 07/3/2025 03:47 PM EasternExtended Trading$8.87 +0.10 (+1.20%) As of 07/3/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Taysha Gene Therapies NASDAQ:TSHA$2.40 -0.03 (-1.23%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$2.48 +0.08 (+3.13%) As of 07/3/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.